Parabilis Raises $845 Million Through IPO and Private Placement

Parabilis Medicines, Inc., a clinical-stage biopharmaceutical company focused on developing therapies against historically difficult-to-target disease-driving proteins, has successfully completed an upsized initial public offering (IPO) and a concurrent private placement, raising approximately $845 million in gross proceeds to accelerate its drug development programs.

The company announced the closing of its IPO, which included the full exercise of the underwriters’ overallotment option. In total, Parabilis sold 38.5 million shares of common stock at a public offering price of $20 per share, generating gross proceeds of approximately $770.5 million before underwriting discounts, commissions, and other offering-related expenses.

Parabilis’ common stock began trading on the Nasdaq Global Select Market on June 10, 2026, under the ticker symbol “PBLS.” The offering attracted significant investor interest, prompting the company to increase the size of the deal and allowing underwriters to exercise their option to purchase an additional 5.025 million shares in full.

In a further boost to its capital position, the company also completed a concurrent private placement with Regeneron Pharmaceuticals. Under the agreement, Regeneron purchased 4.17 million shares of Parabilis common stock at $18 per share, representing 90% of the IPO price. The transaction generated an additional $75 million in proceeds for Parabilis and further strengthened the company’s relationship with one of the biotechnology industry’s leading players.

Combined, the IPO and private placement raised roughly $845.5 million in gross proceeds, providing Parabilis with substantial financial resources to advance its pipeline and expand its research and development efforts.

The company stated that the financing marks another milestone in what has been a transformative year. Including public and private financings as well as strategic collaborations completed during 2026, Parabilis has now secured more than $1.2 billion in funding before fees and expenses. The capital is expected to support the company’s mission of developing innovative medicines targeting some of the most consequential biological pathways in human disease.

Parabilis specializes in addressing protein targets that have historically been considered “undruggable,” a category of disease-driving proteins that have proven difficult to modulate using traditional therapeutic approaches. Advances in drug discovery technologies have increasingly enabled biotechnology companies to revisit these targets, creating new opportunities for treatments across oncology, immunology, and other serious disease areas.

The IPO also triggered the automatic conversion of all outstanding preferred shares into common stock. In addition, a $50 million Simple Agreement for Future Equity (SAFE) held by Explore Investments LLC converted into common stock as part of the company’s transition to a publicly traded entity.

The offering was led by a syndicate of major investment banks. Leerink Partners, BofA Securities, Evercore ISI, and Guggenheim Securities served as active book-running managers, while LifeSci Capital acted as a passive book-running manager.

The successful debut highlights continued investor appetite for biotechnology companies with differentiated scientific platforms and ambitious development pipelines. With a strengthened balance sheet and access to public capital markets, Parabilis is now positioned to advance its clinical programs and pursue its long-term goal of delivering transformative therapies for patients with serious and difficult-to-treat diseases.

The company’s strong market debut also underscores growing confidence in innovative drug discovery approaches aimed at unlocking previously inaccessible therapeutic targets, an area that many industry observers view as a major frontier for future pharmaceutical innovation.